Related Experiment Video

Updated: May 3, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.1K

Mepolizumab in chronic rhinosinusitis with severe nasal polyposis: Real-life Spanish cohort study

Paula Cruz Toro1, Mireia Golet Fors2, Albert Llansana Ríos3

  • 1Department of Otorhinolaryngology, Hospital Universitari Germans Trias i Pujol, Spain; Department of Clinical Sciences, Bellvitge Campus, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain; Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain.

Acta Otorrinolaringologica Espanola
|March 9, 2026
PubMed
Abstract

Insights

Mepolizumab treatment significantly improved nasal symptoms and polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This biologic therapy demonstrated safety and efficacy over 12 months, with potential for olfactory recovery with longer use.

Area of Science:

  • Immunology
  • Otolaryngology
  • Pharmacology

Background:

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammation-driven condition impacting quality of life.
  • Severe CRSwNP often sees symptom recurrence despite standard therapies.
  • Mepolizumab, an anti-interleukin-5 (IL-5) monoclonal antibody, shows promise in managing CRSwNP.

Purpose of the Study:

  • To evaluate the real-world effectiveness and safety of mepolizumab in CRSwNP patients over 12 months.
  • To assess mepolizumab's impact on nasal symptoms, polyp size, and olfactory function.
  • To compare outcomes in CRSwNP patients with and without comorbid asthma.

Main Methods:

  • A prospective observational study involving 28 adult CRSwNP patients treated with mepolizumab (100 mg SC every 4 weeks).
  • Standardized assessments included Nasal Polyp Score (NPS), SNOT-22, VAS, and Sniffin' Sticks Smell Test at baseline, 6, and 12 months.
  • Monitoring of blood eosinophil counts and adverse events.

Main Results:

  • Significant improvements in NPS, SNOT-22, and symptom VAS were observed at 6 and 12 months (p < 0.05).
  • Olfactory function showed significant improvement at 12 months.
  • Mepolizumab led to a sharp decrease in blood eosinophils, with no serious adverse events reported. Patients with asthma and AERD experienced greater benefits.

Conclusions:

  • Mepolizumab is a safe and effective treatment for severe CRSwNP, yielding significant clinical and endoscopic improvements.
  • The observed olfactory gains suggest that extended mepolizumab treatment may be necessary for full sensory recovery.
  • Real-world data supports mepolizumab's utility in managing CRSwNP, including comorbid asthma.
Keywords:
Chronic rhinosinusitis with nasal polypsMepolizumabOlfactionOlfatoRinosinusitis crònica con poliposis nasosinusalSniffin' sticksSniffin’ sticks

More Related Videos

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation06:13

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation

Published on: June 20, 2018

18.2K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

3.1K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
49
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
48
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
40
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet...
30